| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Cogent Biosciences, Inc. | Director | Series A Convertible Preferred Stock | 67,414 | $598,636,320 | $8880.00 | 22 Jan 2026 | Fairmount Healthcare Fund II LP |
| Cogent Biosciences, Inc. | Director | Common Stock | 5,503,418 | $200,324,415 | $36.40 | 22 Jan 2026 | Fairmount Healthcare Fund II LP |
| Viridian Therapeutics, Inc.\DE | Director, 10%+ Owner | Common Stock | 3,914,458 | $86,118,076 | $22.00 | 23 Oct 2025 | Fairmount Healthcare Fund II LP |
| Zenas BioPharma, Inc. | Director | Common Stock | 2,209,025 | $41,971,475 | $19.00 | 07 Oct 2025 | By Fairmount Healthcare Fund II L.P. |
| Oruka Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 2,573,308 | $37,338,699 | $14.51 | 17 Sep 2025 | By Fairmount Healthcare Co-Invest III L.P. |
| CRESCENT BIOPHARMA, INC. | Director, 10%+ Owner | Ordinary Shares | 2,747,866 | $36,848,883 | $13.41 | 04 Dec 2025 | By Fairmount Healthcare Fund II L.P. |
| Dianthus Therapeutics, Inc. /DE/ | Director | Common Stock | 2,700,691 | $32,408,292 | $12.00 | 27 Sep 2024 | By Fairmount Healthcare Fund II L.P. |
| CRESCENT BIOPHARMA, INC. | Director, 10%+ Owner | Pre-Funded Warrant (Right to Buy) | 1,768,140 | $23,708,989 | $13.41 | 04 Dec 2025 | By Fairmount Healthcare Fund II L.P. |
| Jade Biosciences, Inc. | Director, 10%+ Owner | Common Stock | 2,655,817 | $22,924,746 | $8.63 | 06 Oct 2025 | By Fairmount Healthcare Co-Invest IV L.P. |
| Apogee Therapeutics, Inc. | Director | Common Stock | 298,647 | $22,786,766 | $76.30 | 22 Jan 2026 | By Fairmount Healthcare Fund II LP |
| Jade Biosciences, Inc. | Director, 10%+ Owner | Common Stock | 1,897,677 | $17,344,767 | $9.14 | 06 Oct 2025 | By Fairmount Healthcare Fund II L.P. |
| Oruka Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 1,131,954 | $16,979,310 | $15.00 | 17 Sep 2025 | By Fairmount Healthcare Fund II L.P. |
| Dianthus Therapeutics, Inc. /DE/ | Director | Pre-Funded Warrants (Right to Buy) | 832,333 | $9,987,164 | $12.00 | 22 Jan 2024 | Indirect |
| Jade Biosciences, Inc. | Director, 10%+ Owner | Pre-Funded Warrant (Right to Buy) | 855,047 | $7,815,044 | $9.14 | 06 Oct 2025 | By Fairmount Healthcare Fund II L.P. |
| Apogee Therapeutics, Inc. | Director | Common Stock | 51,166 | $3,862,019 | $75.48 | 22 Jan 2026 | By Peter Harwin |
| Apogee Therapeutics, Inc. | Director | Common Stock | 51,166 | $3,862,019 | $75.48 | 22 Jan 2026 | By Tomas Kiselak |
| Dianthus Therapeutics, Inc. /DE/ | Director | Common Stock | 0 | $0 | $12.00 | 27 Sep 2024 | By Fairmount SPV III, LLC |
| Oruka Therapeutics, Inc. | Director, 10%+ Owner | Series A Non-Voting Convertible Preferred Stock | 0 | $0 | $23000.00 | 19 Nov 2024 | By Fairmount Healthcare Fund II L.P. |
| Spyre Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25,000 | 29 May 2025 | By Peter Harwin | ||
| Spyre Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25,000 | 29 May 2025 | By Tomas Kiselak | ||
| Aerovate Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 23,017 | 29 Apr 2025 | Direct | ||
| Zenas BioPharma, Inc. | Director | Stock Option (Right to Buy) | 18,500 | 10 Jun 2025 | By Tomas Kiselak | ||
| Oruka Therapeutics, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 17,500 | 02 Jun 2025 | By: Peter Harwin | ||
| Apogee Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 14,461 | 17 Jun 2025 | By: Peter Harwin | ||
| Apogee Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 14,461 | 17 Jun 2025 | By: Tomas Kiselak | ||
| Dianthus Therapeutics, Inc. /DE/ | Director | Stock Option (Right to Buy) | 11,000 | 23 May 2024 | Indirect | ||
| CRESCENT BIOPHARMA, INC. | Director, 10%+ Owner | Stock Option (Right to Buy) | 9,023 | 23 Jun 2025 | By: Peter Harwin | ||
| Viridian Therapeutics, Inc.\DE | Director, 10%+ Owner | Stock Option (Right to Buy) | 0 | 10 Jun 2025 | By: Peter Harwin |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | 22 Jan 2026 | 1 | -$127,400,000 | 4 | Director | 22 Jan 2026, 20:09 |
| APGE | Apogee Therapeutics, Inc. | 22 Jan 2026 | 1 | -$133,525,000 | 4 | Director | 22 Jan 2026, 20:07 |
| GLYC | CRESCENT BIOPHARMA, INC. | 04 Dec 2025 | 2 | +$19,999,999 | 4 | Director, 10%+ Owner | 08 Dec 2025, 16:30 |
| GLTO | Galecto, Inc. | 10 Nov 2025 | 0 | $0 | 3 | Director, 10%+ Owner | 17 Nov 2025, 21:48 |
| VRDN | Viridian Therapeutics, Inc.\DE | 23 Oct 2025 | 1 | +$9,999,990 | 4 | Director, 10%+ Owner | 27 Oct 2025, 16:30 |
| ZBIO | Zenas BioPharma, Inc. | 07 Oct 2025 | 1 | +$6,008,161 | 4 | Director | 09 Oct 2025, 16:15 |
| JBIO | Jade Biosciences, Inc. | 06 Oct 2025 | 2 | +$19,999,816 | 4 | Director, 10%+ Owner | 08 Oct 2025, 16:15 |
| ORKA | Oruka Therapeutics, Inc. | 17 Sep 2025 | 1 | +$5,000,100 | 4 | Director, 10%+ Owner | 19 Sep 2025, 17:33 |
| COGT | Cogent Biosciences, Inc. | 10 Jul 2025 | 1 | +$24,999,993 | 4 | Director | 14 Jul 2025, 16:30 |
| GLYC | GLYCOMIMETICS INC | 23 Jun 2025 | 1 | $0 | 4 | Director, 10%+ Owner | 23 Jun 2025, 18:48 |
| APGE | Apogee Therapeutics, Inc. | 17 Jun 2025 | 2 | $0 | 4 | Director | 20 Jun 2025, 20:06 |
| GLYC | GLYCOMIMETICS INC | 13 Jun 2025 | 0 | $0 | 3 | Director, 10%+ Owner | 23 Jun 2025, 18:25 |
| ZBIO | Zenas BioPharma, Inc. | 10 Jun 2025 | 1 | $0 | 4 | Director | 12 Jun 2025, 16:34 |
| VRDN | Viridian Therapeutics, Inc.\DE | 09 Jun 2025 | 4 | +$166,355 | 4 | Director, 10%+ Owner | 11 Jun 2025, 17:00 |
| ORKA | Oruka Therapeutics, Inc. | 02 Jun 2025 | 1 | $0 | 4 | Director, 10%+ Owner | 03 Jun 2025, 16:30 |
| SYRE | Spyre Therapeutics, Inc. | 29 May 2025 | 2 | $0 | 4 | Director | 02 Jun 2025, 16:39 |
| JBIO | Jade Biosciences, Inc. | 29 Apr 2025 | 1 | $0 | 4 | Director, 10%+ Owner | 01 May 2025, 18:16 |
| JBIO | Jade Biosciences, Inc. | 28 Apr 2025 | 0 | $0 | 3 | Director, 10%+ Owner | 01 May 2025, 17:58 |
| ORKA | Oruka Therapeutics, Inc. | 19 Nov 2024 | 2 | $0 | 4 | Director, 10%+ Owner | 21 Nov 2024, 18:30 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 27 Sep 2024 | 1 | $0 | 4 | Director | 01 Oct 2024, 20:00 |
| VRDN | Viridian Therapeutics, Inc.\DE | 13 Sep 2024 | 1 | +$30,000,000 | 4 | Director, 10%+ Owner | 17 Sep 2024, 21:00 |
| ZBIO | Zenas BioPharma, Inc. | 12 Sep 2024 | 10 | +$5,100,000 | 4/A | Director | 17 Sep 2024, 20:56 |
| ZBIO | Zenas BioPharma, Inc. | 12 Sep 2024 | 0 | $0 | 3 | Director, 10%+ Owner | 12 Sep 2024, 21:41 |
| ORKA | Oruka Therapeutics, Inc. | 11 Sep 2024 | 2 | +$10,005,000 | 4 | Director, 10%+ Owner | 13 Sep 2024, 16:55 |
| ORKA | Oruka Therapeutics, Inc. | 29 Aug 2024 | 0 | $0 | 3 | Director, 10%+ Owner | 06 Sep 2024, 17:07 |
| COGT | Cogent Biosciences, Inc. | 10 Jun 2024 | 2 | $0 | 4 | Director | 12 Jun 2024, 21:01 |
| APGE | Apogee Therapeutics, Inc. | 05 Jun 2024 | 2 | $0 | 4 | Director | 07 Jun 2024, 20:00 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 23 May 2024 | 1 | $0 | 4 | Director | 28 May 2024, 19:57 |
| SYRE | Spyre Therapeutics, Inc. | 14 May 2024 | 2 | $0 | 4 | Director | 16 May 2024, 16:10 |
| SYRE | Spyre Therapeutics, Inc. | 25 Apr 2024 | 2 | $0 | 4 | Director | 25 Apr 2024, 16:55 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 01 Apr 2024 | 2 | $0 | 4 | Director | 01 Apr 2024, 18:21 |
| VRDN | Viridian Therapeutics, Inc.\DE | 28 Mar 2024 | 4 | $0 | 4 | Director, 10%+ Owner | 01 Apr 2024, 18:32 |
| COGT | Cogent Biosciences, Inc. | 28 Mar 2024 | 4 | $0 | 4 | Director | 01 Apr 2024, 18:19 |
| APGE | Apogee Therapeutics, Inc. | 28 Mar 2024 | 4 | $0 | 4 | Director | 01 Apr 2024, 17:44 |
| COGT | Cogent Biosciences, Inc. | 16 Feb 2024 | 2 | +$19,999,995 | 4 | 10%+ Owner | 16 Feb 2024, 18:43 |
| APGE | Apogee Therapeutics, Inc. | 29 Jan 2024 | 3 | $0 | 4 | Director | 31 Jan 2024, 16:31 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 22 Jan 2024 | 2 | +$19,999,172 | 4 | Director, 10%+ Owner | 24 Jan 2024, 19:02 |
| VRDN | Viridian Therapeutics, Inc.\DE | 22 Jan 2024 | 1 | +$9,999,990 | 4 | Director, Other*, 10%+ Owner | 24 Jan 2024, 18:44 |
| SYRE | Spyre Therapeutics, Inc. | 29 Dec 2023 | 3 | $0 | 4 | Director, 10%+ Owner | 29 Dec 2023, 17:00 |
| SYRE | Spyre Therapeutics, Inc. | 07 Dec 2023 | 1 | +$10,000,200 | 4 | Director, 10%+ Owner | 11 Dec 2023, 17:41 |
| SYRE | Spyre Therapeutics, Inc. | 24 Nov 2023 | 2 | $0 | 4 | Director, 10%+ Owner | 28 Nov 2023, 16:05 |
| VRDN | Viridian Therapeutics, Inc.\DE | 30 Oct 2023 | 1 | +$40,000,129 | 4 | Director, Other*, 10%+ Owner | 01 Nov 2023, 21:05 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 29 Sep 2023 | 1 | +$336,252 | 4 | Director, 10%+ Owner | 03 Oct 2023, 16:00 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 26 Sep 2023 | 1 | +$394,500 | 4 | Director, 10%+ Owner | 28 Sep 2023, 18:09 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 19 Sep 2023 | 1 | +$396,000 | 4 | Director, 10%+ Owner | 21 Sep 2023, 17:23 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 11 Sep 2023 | 3 | +$271,680 | 4 | Director, 10%+ Owner | 13 Sep 2023, 22:17 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | 11 Sep 2023 | 0 | $0 | 3 | Director, 10%+ Owner | 13 Sep 2023, 21:55 |
| APGE | Apogee Therapeutics, Inc. | 13 Jul 2023 | 5 | +$49,999,992 | 4 | Director | 17 Jul 2023, 20:00 |
| APGE | Apogee Therapeutics, Inc. | 13 Jul 2023 | 0 | $0 | 3 | Director | 13 Jul 2023, 18:39 |
| SYRE | Aeglea BioTherapeutics, Inc. | 22 Jun 2023 | 0 | $0 | 3 | Director, 10%+ Owner | 30 Jun 2023, 17:32 |
| COGT | Cogent Biosciences, Inc. | 09 Jun 2023 | 1 | +$9,600,000 | 4 | Other*, 10%+ Owner | 13 Jun 2023, 16:07 |
| VRDN | Viridian Therapeutics, Inc.\DE | 17 Aug 2022 | 1 | +$9,999,978 | 4 | Director, Other*, 10%+ Owner | 19 Aug 2022, 16:32 |
| COGT | Cogent Biosciences, Inc. | 16 Jun 2022 | 1 | +$9,900,000 | 4 | Other*, 10%+ Owner | 21 Jun 2022, 10:02 |
| VRDN | Viridian Therapeutics, Inc.\DE | 21 Sep 2021 | 1 | +$9,999,000 | 4 | Director, 10%+ Owner | 23 Sep 2021, 09:30 |